Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (34590)	5/17/2007 3:59:41 PM
From: Rangle	Respond to of 48461

DNDN me too....gotta be in it to win it,... hope they dn't get that approval tomorrow heh heh

To: Bucky Katt who wrote (34590)	5/20/2007 10:54:01 PM
From: Fudd	Respond to of 48461

Dendreon Announces Presentation of Data at American Urological Association Annual Meeting Sunday May 20, 6:30 pm ET -Data May Support Use of PROVENGE(R) as Front-line Treatment in Advanced Prostate Cancer- biz.yahoo.com According to the analysis, the patients who received initial treatment with PROVENGE followed by docetaxel had a median survival of 34.5 months compared to 25.4 months for those patients in the placebo arm who received treatment with docetaxel chemotherapy, a 9.1 month difference. In addition, an analysis of overall survival demonstrated that patients in the PROVENGE arm who received subsequent therapy with docetaxel had a 47 percent reduction in their risk of death compared to those in the placebo arm who received subsequent therapy with docetaxel (HR = 1.90, p-value = 0.023).